Added to YB: 2026-01-09
Pitch date: 2026-01-06
GOSS [bearish]
Gossamer Bio, Inc.
+83.4%
current return
Author Info
Molecule -> Market is a financial analyst specializing in pharmaceutical and biotechnology companies. I publish detailed research on biotech stocks, using DCF modeling, clinical trial analysis, and market positioning data. Sign up for the newsletter.
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.
Market Cap
$523.1M
Pitch Price
$2.55
Price Target
1.00 (+136%)
Dividend
N/A
EV/EBITDA
-3.62
P/E
-3.29
EV/Sales
12.39
Sector
Biotechnology
Category
N/A
Why Gossamer Bio is Unlikely to Remodel the PAH Market
GOSS (bearish): Inhaled TKI seralutinib for PAH faces high Phase 3 failure risk. Small Phase 2 signal (95 dyne PVR reduction vs 225+ for approved drugs) relied on FC III subgroup & unusual placebo deterioration. Inhaled delivery unlikely reaches vascular lesions needing remodeling. Even if successful, faces dominant sotatercept competition & cough issues. $650M mcap vs $180M cash burning $35-40M/qtr.
Read full article (10 min)